Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INHALEd Nebulised Unfractionated HEParin for the Treatment of Hospitalised Patients With COVID-19 (INHALE-HEP) Australia

NCT05184101 is registered in ClinicalTrials.gov with Australian National University as lead sponsor.

NCT NCT05184101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05184101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INHALEd Nebulised Unfractionated HEParin for the Treatment of Hospitalised Patients With COVID-19 (INHALE-HEP) Australia
Lead sponsor
Australian National University
Phase
Phase 2/3
Overall status
Withdrawn
Start date
August 31, 2023
Completion date
March 1, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19